In a study analyzing plasma samples from 17 patients with MM receiving CAR‐T therapy, researchers identified LPCAT1 as a potential metabolic target in MM.[153] Moreover, another study involving 20 patients with B‐ALL identified phosphatidylethanolamine, carnitine C12:1, and 1‐methylguanine as metabolic biomarkers that distinguished CR from non‐CR cases, highlighting the predictive value of metabolomics in CAR‐T therapy outcomes.[149]. Here, LPCAT1 is linked to Miyoshi myopathy.